Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L Purchases 150,000 Shares

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 150,000 shares of the stock in a transaction dated Monday, August 26th. The stock was acquired at an average cost of $2.15 per share, with a total value of $322,500.00. Following the purchase, the director now owns 53,775,821 shares of the company’s stock, valued at approximately $115,618,015.15. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Friday, August 23rd, Casdin Partners Master Fund, L purchased 292,100 shares of Standard BioTools stock. The stock was acquired at an average price of $2.13 per share, with a total value of $622,173.00.
• On Wednesday, August 21st, Casdin Partners Master Fund, L bought 500,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.90 per share, with a total value of $950,000.00.
• On Monday, August 19th, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.85 per share, for a total transaction of $462,500.00.
• On Wednesday, August 14th, Casdin Partners Master Fund, L acquired 1,200,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.59 per share, with a total value of $1,908,000.00.
• On Monday, August 12th, Casdin Partners Master Fund, L acquired 500,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.64 per share, for a total transaction of $820,000.00.
• On Friday, August 9th, Casdin Partners Master Fund, L acquired 525,408 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.61 per share, with a total value of $845,906.88.
• On Wednesday, August 7th, Casdin Partners Master Fund, L bought 500,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.57 per share, for a total transaction of $785,000.00.
• On Friday, August 2nd, Casdin Partners Master Fund, L purchased 1,000,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.63 per share, with a total value of $1,630,000.00.
• On Monday, August 5th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.58 per share, for a total transaction of $316,000.00.

Standard BioTools Stock Performance

Shares of LAB stock traded up $0.03 during mid-day trading on Monday, hitting $2.17. 1,711,023 shares of the stock were exchanged, compared to its average volume of 2,698,171. The stock’s fifty day simple moving average is $1.92 and its two-hundred day simple moving average is $2.32. Standard BioTools Inc. has a 12-month low of $1.21 and a 12-month high of $3.16. The stock has a market capitalization of $803.81 million, a price-to-earnings ratio of -2.15 and a beta of 1.67.

Standard BioTools (NASDAQ:LAB) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Standard BioTools had a negative return on equity of 88.47% and a negative net margin of 87.05%. The company had revenue of $37.21 million for the quarter, compared to analyst estimates of $48.15 million. On average, research analysts expect that Standard BioTools Inc. will post -0.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, TD Cowen lowered their price target on Standard BioTools from $3.50 to $2.75 and set a “buy” rating for the company in a report on Thursday, August 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LAB. Vanguard Group Inc. boosted its holdings in shares of Standard BioTools by 215.3% in the first quarter. Vanguard Group Inc. now owns 13,034,043 shares of the company’s stock valued at $35,322,000 after acquiring an additional 8,900,104 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Standard BioTools in the 1st quarter valued at approximately $23,993,000. Swiss National Bank acquired a new position in Standard BioTools during the 1st quarter worth approximately $1,162,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Standard BioTools during the 4th quarter worth approximately $55,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Standard BioTools by 783.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 578,439 shares of the company’s stock worth $1,568,000 after buying an additional 512,937 shares in the last quarter. 53.74% of the stock is owned by hedge funds and other institutional investors.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.